UNSPSC 51292602: Zomebazam

This classification denotes an anxiolytic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G563Y6G60K. European Medicines Agency schedules Zomebazam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00184MIG. Zomebazam generally arises in the molecular formula C15H16N4O2.

The term ZOMEBAZAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) ZOMEBAZAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zomebazam under HS 29337900 and SITC 51561. As of Q4 2014, ZOMEBAZAM remains the US FDA Preferred Term for this commodity. Zomebazam bears US NLM identifiers UMLS ID C1883611 and NCI Concept Code C66708. SMILES: O=C1N(C2C(N(C(=O)C1)C)N(NC2C)C)C1CCCCC1.

UNSPSC 51292602 Zomebazam is a Commodity code that state and local governments use to procure pharmaceutical products, including naloxone, safe drug deactivation systems, generic multi-source medications, and over-the-counter products through competitive bidding and cooperative purchasing agreements. The work encompasses both direct purchase of emergency pharmaceutical supplies for community health initiatives and participation in multi-state cooperative frameworks that aggregate demand across dozens of jurisdictions. Issuing bodies include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple states and local governments. The solicitations show state governments (Florida, Texas, Minnesota) and county-level health authorities using the code to source medications and related health products, with Minnesota's MMCAP cooperative purchasing vehicle serving as a model for multi-jurisdictional pharmaceutical procurement that extends into Oregon and other participant states.

Recent opportunities span emergency pharmaceutical response and routine pharmaceutical supply management. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building, requiring bidders to include shipping costs and comply with E-Verify and drug-free workplace certification. The Texas Health and Human Services Commission posted a Request for Information (HHS0017013, April 3, 2026) to explore vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit managers and wholesalers, gathering market intelligence before formal procurement. The Minnesota Department of Administration's MMCAP issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed through three authorized wholesalers across participating state and local facilities, with evaluation weighted 75 percent on price competitiveness, requiring cGMP and Drug Supply Chain Security Act compliance, and establishing contract terms of two years for new vendors with optional extensions. The geographic activity centers on Florida, Texas, and Minnesota, with multi-state cooperative purchasing extending procurement reach across the Upper Midwest and beyond.